➤ FDA approval for treatment of wet AMD ➤ Patient enrollment complete for 510(k) pivotal study for microshunt ➤ Key findings in using PROSE for NK ➤ Successful End-of-Phase 1 Type B meeting for non-atropine eye drop ➤ Digital journal invites original case report submissions ➤ Company news ➤ ASCRS news and events
➤ FDA accepts BLA for thyroid eye treatment ➤ Breakthrough Therapy Designation granted to investigational neuroprotective for optic neuropathies ➤ FDA issues complete response letter for wet AMD BLA resubmission ➤ Biosimilar approved for retinal therapies ➤ FDA approves IND for corneal genome editing program ➤ Study: ‘largest prospective trial ever’ on postcataract endophthalmitis prophylaxis ➤ Complimentary access to video journal ➤ Company news ➤ ASCRS news and events
➤ Phase 2 results for autoimmune-related dry eye disease immunomodulator ➤ JCRS astigmatism working group publishes two papers ➤ FDA approves therapy for diabetic retinopathy ➤ Enrollment closes for largest retinal trial of its kind to date ➤ Enrollment complete for Phase 3 trial evaluating wet AMD treatment ➤ Rare Pediatric Disease Designation granted for treatment targeting several retinopathies ➤ ASCRS news and events
➤ Update on safety review of geographic atrophy drug ➤ IND application accepted by FDA for wet AMD gene therapy ➤ Phase 2 trial planned for investigational neuropathic corneal pain treatment ➤ Interim Phase 2 data for sustained wet AMD treatment ➤ ASCRS news and events
Get the latest ophthalmology news delivered to your inbox every Friday.